Market Place
Sourcing Support
Theratechnologies Receives March 2025 PDUFA Date
10 Dec 2024 //
GLOBENEWSWIRE
Theratechnologies Submit Updated Tesamorelin F8 sBLA for FDA Review
26 Nov 2024 //
GLOBENEWSWIRE
Theratechnologies Warns Of Egrifta Supply Disruption After Plant Shutdown
18 Sep 2024 //
FIERCE PHARMA
Theratechnologies Announces Risk of EGRIFTA SV® Supply Disruption
17 Sep 2024 //
GLOBENEWSWIRE
FDA declines to approve new form of HIV-associated lipodystrophy drug
25 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Receives Update from FDA on Tesamorelin F8 sBLA
23 Jan 2024 //
GLOBENEWSWIRE
Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin
04 Oct 2023 //
GLOBENEWSWIRE
Theratechnologies Announces That Data On The Mechanism Of Effect Of Tesamorelin
06 Nov 2020 //
THERATECH
Injectable hormone tesamorelin reduces liver fat and prevents liver fibrosis
16 Oct 2019 //
PHARMABIZ
Drug reverses signs of liver disease in people living with HIV
15 Oct 2019 //
PRESS RELEASE
Enforcement Report - Week of November 14, 2018
14 Nov 2018 //
FDA
Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.